

SUMMARY

paracetamol

**EFFERALGANMED
PAEDIATRIC 30 mg/ml**

Oral solution

Modification of the listing conditions

Original French opinion adopted by the Transparency Committee on
24 April 2024

The legally binding text is the original French opinion version

Summary of opinion

Favourable opinion for maintenance of reimbursement in “the symptomatic treatment of mild to moderate pain and/or fever. This form is RESERVED FOR CHILDREN weighing from 3 to 32 kg (from birth to around 12 years)”.

Transparency Committee’s conclusions**Clinical Benefit**

The Committee considers that the clinical benefit of EFFERALGANMED 30 mg/ml oral solution is substantial in the MA indication.

This document and its bibliographic reference are available to download at www.has-sante.fr 

This opinion is published subject to intellectual property rights

Haute Autorité de Santé – Communication and Information Department

5 avenue du Stade de France – 93218 SAINT-DENIS LA PLAINE CEDEX – France. Tel.: +33 (0)1 55 93 70 00

© Haute Autorité de santé – April 2024

The Committee issues a favourable opinion for maintenance of inclusion in both the list of covered drugs for outpatients and the list of covered drugs for inpatients approved for use in the indication and at the MA dosages.

→ Recommended reimbursement rate for inclusion in the list of covered drugs for outpatients: 65%